Qiagen NV (NASDAQ:QGEN) belonging to the Medical sector has declined -4.1% and closed its last trading session at $26.44.
The company reported its last EPS on 9/30/2016 and is expected to report its next EPS on Nov 02 AMC. Currently, the stock has a 1 Year Price Target of $26.65.
The consensus recommendation, according to Zacks Investment research, is 2.63. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2.59 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.59 and 2.75 respectively.
Qiagen NV on 9/30/2016 reported its EPS as $0.24 with the analysts projecting the EPS of the stock as $0.23. The company beat the analyst EPS Estimate with the difference of $0.01. This shows a surprise factor of 4.3%.
Many analysts have provided their estimated foresights on Qiagen NV Earnings, with 11 analysts believing the company would generate an Average Estimate of $0.28. Whereas they predicted High and Low Earnings Estimate as $0.29 and $0.26 respectively. While in the same Quarter Previous year, the Actual EPS was $0.27.
Analysts are also projecting an Average Revenue Estimate for Qiagen NV as $335.46 Million in the Current Quarter. This estimate is provided by 10 analysts. The High Revenue estimate is predicted as 338 Million, while the Low Revenue Estimate prediction stands at 330.6 Million. The company’s last year sales total was 314.56 Million.
For the Current Quarter, the growth estimate for Qiagen NV is 3.7%, while for the Next Quarter the stock growth estimate is 25.8%. In the past 5 years, the stock showed growth of 1.15% per annum. While for the next 5 years, the growth estimate is 9.82%.
The Company got Upgrade by HSBC Securities on 1-Aug-16 from Hold to Buy.
10 analysts projected Price Targets for Qiagen NV. The analysts believe that the company stock price could grow as high as $30. The Low Price target projection by analysts is $24 and the Mean Price Target is $26.65.
Qiagen NV (NASDAQ:QGEN) has the market capitalization of $6.34 Billion. The company rocked its 52-Week High of $28.04 on Dec 31, 2015 and touched its 52-Week Low of $19.94 on Jun 27, 2016. The stock has Return on Assets (ROA) of 2.9 percent. Return on Equity (ROE) stands at 4.6% and Return on Investment (ROI) of 4.7 percent.
The stock is currently showing YTD performance of -4.38 Percent. The company has Beta Value of 1.02 and ATR value of 0.51. The Weekly and Monthly Volatility stands at 1.75% and 1.82%.
Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.